Results 161 to 170 of about 9,011 (201)
Journal of Pediatric Intensive Care, 2015 We designed this review to examine the mechanism of action of levosimendan (Simdax®, Orion Pharma, Espoo, Finland) and its current clinical application in critically ill adults and children with acutely decompensated severe congestive heart failure and who require inotropic support.
Asher, Levin, Gideon, Paret
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2001
Levosimendan, a pyridazinone-dinitrile derivative, is a calcium sensitiser with additional action on adenosine triphosphate (ATP)-sensitive potassium channels. It is used intravenously (IV) for the treatment of decompensated cardiac failure. At therapeutic doses, levosimendan exhibits enhanced contractility with no increase in oxygen demands.
D P, Figgitt, P S, Gillies, K L, Goa
+5 more sources
Levosimendan, a pyridazinone-dinitrile derivative, is a calcium sensitiser with additional action on adenosine triphosphate (ATP)-sensitive potassium channels. It is used intravenously (IV) for the treatment of decompensated cardiac failure. At therapeutic doses, levosimendan exhibits enhanced contractility with no increase in oxygen demands.
D P, Figgitt, P S, Gillies, K L, Goa
+5 more sources
Current Pharmaceutical Design, 2013
During the last years an increasing number of patients with high perioperative risk and decreased left ventricular function are referred to cardiac and non-cardiac surgery. In this subgroup of patients, heart failure is the major cause of perioperative morbidity and mortality. In order to prevent and treat this type of complications several therapeutic
Andrea, Rognoni +7 more
openaire +2 more sources
During the last years an increasing number of patients with high perioperative risk and decreased left ventricular function are referred to cardiac and non-cardiac surgery. In this subgroup of patients, heart failure is the major cause of perioperative morbidity and mortality. In order to prevent and treat this type of complications several therapeutic
Andrea, Rognoni +7 more
openaire +2 more sources
Levosimendan Following Cardiac Surgery
Heart, Lung and Circulation, 2019A best evidence topic was written to address if perioperative levosimendan improves mortality following cardiac surgery. Fourteen papers represented the best available evidence. An older meta-analysis summarising 11 of these trials concluded that there were fewer deaths in the levosimendan group compared to the control group (OR 0.41, p
Sean M, Conte +4 more
openaire +2 more sources